Insider Selling: Tempus AI, Inc. (NASDAQ:TEM) Director Sells 990 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) Director David R. Epstein sold 990 shares of Tempus AI stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $46.83, for a total transaction of $46,361.70. Following the completion of the transaction, the director now directly owns 26,284 shares in the company, valued at approximately $1,230,879.72. This represents a 3.63 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Tempus AI Stock Performance

TEM opened at $48.04 on Friday. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. The firm’s fifty day moving average price is $56.07 and its two-hundred day moving average price is $51.45. Tempus AI, Inc. has a fifty-two week low of $22.89 and a fifty-two week high of $91.45.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on TEM shares. Wolfe Research downgraded shares of Tempus AI from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 26th. Guggenheim reiterated a “buy” rating on shares of Tempus AI in a research note on Tuesday, February 25th. Needham & Company LLC boosted their price objective on Tempus AI from $56.00 to $70.00 and gave the stock a “buy” rating in a research report on Tuesday, February 25th. JPMorgan Chase & Co. lowered Tempus AI from an “overweight” rating to a “neutral” rating and raised their target price for the company from $50.00 to $55.00 in a report on Tuesday, February 25th. Finally, Bank of America upped their price target on Tempus AI from $54.00 to $60.00 and gave the stock a “neutral” rating in a report on Monday, March 3rd. Six research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $61.18.

Institutional Investors Weigh In On Tempus AI

Several large investors have recently modified their holdings of TEM. GSA Capital Partners LLP acquired a new stake in Tempus AI in the 3rd quarter valued at $306,000. First Horizon Advisors Inc. acquired a new stake in shares of Tempus AI in the 3rd quarter valued at $30,000. The Manufacturers Life Insurance Company grew its holdings in shares of Tempus AI by 10.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 29,789 shares of the company’s stock worth $1,686,000 after purchasing an additional 2,765 shares during the last quarter. Captrust Financial Advisors acquired a new stake in shares of Tempus AI during the 3rd quarter worth about $2,726,000. Finally, NEA Management Company LLC lifted its holdings in Tempus AI by 17.8% during the 3rd quarter. NEA Management Company LLC now owns 5,385,979 shares of the company’s stock valued at $304,846,000 after purchasing an additional 813,169 shares during the last quarter. 24.22% of the stock is currently owned by institutional investors.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.